Gene Therapy Market
Industry
- Automobile and Transportation
- Chemicals and Materials
- Consumer Goods
- Energy and Power
- Electronics and Semiconductor
- Food and Beverages
- Machinery and Equipment
- Pharma and Healthcare
- Service and Software
- Others
- Packaging
- ICT
- Technology
- Medical Devices and Consumables
- Agriculture
- Medical Care
- Aerospace and Defense
Gene Therapy Market Size, Share & Analysis By Type (Gene Silencing, Cell Replacement, Gene Augmentation, Others), By Gene Type (Antigen, Cytokine, Tumor Suppressor, Deficiency, Growth Factors, Receptors, Others), By Application (Oncological Disorders, Cardiological Diseases, Infectious Diseases, Rare Diseases, Neurological Diseases, Others), By End-Use (Cancer Institutes, Hospitals, Research Centers, Others), By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa), and Growth Forecast To 2032
Report ID: RV85221 | Published: Jan 2024 | Historical Period: 2018-2022 | Pages: 190 | Price: $3260| Industry: Medical Care
Gene Therapy Market Overview 2024:
The global gene therapy market size was USD 8 billion in 2023 and is expected to register a robust CAGR of 19% during the forecast period. Key factors such as growing prevalence of various chronic and genetic diseases, rapid advancements in genetic research, and rising regulatory approvals for gene therapy products are expected to drive global market growth during the forecast period.
Gene therapy is an innovative approach that uses genetic material to treat and prevent diseases. It works by altering a person’s genetic makeup to treat a disease instead of using drugs or surgery. This genetic material may carry a functional gene to replace a defective or mutated one, introduce a new gene, or regulate the expression of existing genes. Various delivery methods such as viral vectors and non-viral vectors are used to transport the genetic material into the target cell.
Gene therapy is widely used across many healthcare centers to treat various genetic diseases such as cystic fibrosis, hemophilia, and muscular dystrophy along with various cancer types, cardiovascular diseases, and neurological diseases. Many companies, institutes, and educational centers are currently working on gene therapy to explore more applications of gene therapy and cure rare diseases.
However, these therapies are costly and require robust research, development, clinical testing, and infrastructure funds. In addition, only a few gene therapies have received regulatory approval and many are in the process.
Graphical Overview:
Key Takeaways:
Technological Advancements in Gene-editing Technologies:
Advanced gene-editing technologies like CRISPR-Cas9 have significantly enhanced the precision and efficiency of gene therapies. Increasing investments by public and private sectors to develop more such effective technologies is expected to drive global market growth going ahead. In addition, the overall healthcare spending and budget are increasing steadily. This is leading to growing adoption of gene therapies across several healthcare sectors.
Limited Availability of Approved Therapies and Ethical and Social Concerns:
Though gene therapy is rapidly gaining popularity, certain challenges in gene delivery, limited availability of approved therapies, and inadequate manufacturing capacity in many developing economies are expected to hamper overall market growth between 2024 and 2032. In addition, growing concerns about potential misuse of gene-editing technologies have resulted in social and ethical dilemmas. This can also limit the adoption of existing gene therapies to a certain extent going ahead.
Market Opportunities:
With the rising prevalence of novel and rare diseases, gene therapy is proving to be a promising solution in addressing rare genetic diseases. This is expected to open new opportunities for key players and new entrants to identify new genetic targets and develop therapies and delivery technologies for a broader array of diseases. In addition, they can focus on market expansions and reach patients in regions with unmet medical needs.
Type Outlook:
Based on type, the global market is segmented into gene silencing, cell replacement, gene augmentation, and others. The gene silencing segment is expected to register robust revenue CAGR over the forecast period owing to rising prevalence of various types of cancer, infectious and neurodegenerative conditions, presence of large number of gene therapy products utilizing gene silencing mechanism, and rising R&D investments.
End Use Outlook:
The global market is segmented into cancer institutes, hospitals, research centers, and others based on end use. Among these end users, the cancer institutes segment is expected to account for the largest revenue share during the forecast period. This growth can be significantly driven by factors such as rising prevalence of various types of cancer, ongoing research on gene therapy for cancer across various institutes, and availability of gene therapy programs, clinical trial facilities, and collaborations with pharmaceutical companies.
Regional Outlook:
North America is expected to account for largest revenue share during the forecast period owing to increasing prevalence of genetic and chronic diseases, rapid advancements in genetic research, and growing adoption of various types of gene-editing technologies. In addition, presence of leading pharma and biotechnology companies, presence of several regulatory agencies, and rising investments and collaborations among companies to develop advanced and effective therapies are expected to drive North America market growth going ahead.
Report Coverage:
| Report Details | Outcome |
| Base Year for Estimation | 2023 |
| Historical Data | 2018-2022 |
| Forecast Period | 2024-2032 |
| Segments Covered | Type, Gene Type, Application, End-Use and Region |
| By Type | Gene Silencing, Cell Replacement, Gene Augmentation, Others |
| By Gene Type | Antigen, Cytokine, Tumor Suppressor, Deficiency, Growth Factors, Receptors, Others |
| By Application | Oncological Disorders, Cardiological Diseases, Infectious Diseases, Rare Diseases, Neurological Diseases, Others |
| By End Use | Cancer Institutes, Hospitals, Research Centers, Others |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Country Scope | United States, Canada, Germany, France, UK, Italy, Russia, China, Japan, South Korea, Southeast Asia, India, Mexico, Brazil, Saudi Arabia, UAE, Turkey |
| Qualitative Info | •Value Chain Analysis •Pricing Analysis •Regional Outlook •Market Trends •Market Share Analysis •Competition Analysis •Technological Advancements |
| Key Players | REGENXBIO, Inc., Oxford BioMedica plc, Dimension Therapeutics, Inc., Bristol-Myers Squibb Company, SANOFI, Applied Genetic Technologies Corporation, F. Hoffmann-La Roche Ltd, bluebird Bio, Inc., Novartis AG, Taxus Cardium Pharmaceuticals Group, Inc., UniQure N.V., Shire Plc., Cellectis S.A., Sangamo Therapeutics, Inc, Orchard Therapeutics, Gilead Lifesciences, Inc., BENITEC BIOPHARMA, Sibiono GeneTech Co., Ltd, Shanghai Sunway Biotech Co., Ltd., Gensight Biologics S.A., Transgene, Calimmune, Inc., Epeius Biotechnologies Corp., Astellas Pharma Inc., American Gene Technologies, BioMarin Pharmaceuticals, Inc. |
| Customization Scope | 10 Hours of Free Customization and Expert Consultation |
Competitive Landscape:
The global Gene Therapy market is extremely competitive, comprising several regional and global level key players. Leading key players are focused on adopting various strategic alliances like mergers and acquisitions, partnerships, joint ventures, collaborations, and product launches to maintain their global position and enhance their product offerings. They are also focused on innovation, and scalability, and are adapting to evolving technology trends and consumer needs.
Some Leading Market Companies Listed in the Report:
- REGENXBIO, Inc.
- Oxford BioMedica plc
- Dimension Therapeutics, Inc.
- Bristol-Myers Squibb Company
- SANOFI
- Applied Genetic Technologies Corporation
- Hoffmann-La Roche Ltd
- Bluebird Bio, Inc.
- Novartis AG
- Taxus Cardium Pharmaceuticals Group, Inc.
- UniQure N.V.
- Shire Plc
- Cellectis S.A.
- Sangamo Therapeutics, Inc
- Orchard Therapeutics
- Gilead Lifesciences, Inc.
- BENITEC BIOPHARMA
- Sibiono GeneTech Co., Ltd
- Shanghai Sunway Biotech Co., Ltd.
- Gensight Biologics S.A.
- Transgene
- Calimmune, Inc.
- Epeius Biotechnologies Corp.
- Astellas Pharma Inc.
- American Gene Technologies
- BioMarin Pharmaceuticals, Inc.
Gene Therapy Industry Recent Developments:
- In January 2024, Ginkgo Bioworks and Biogen announced
- In December 2023, the FDA approved first gene therapies; Casgevy and Lyfgenia to treat patients with sickle cell disease in patients 12 years and old.
- In June 2023, Laurus Labs Ltd. announced its plans to launch gene therapy assets in India. It has linked a MoA with IIT Kanpur for the in-licensing of novel gene therapy assets using the Adeno Adeno-associated virus.
- In April 2023, AmerisourceBergen announced the launch of its Cell and Gene Therapy (CGT) Integration Hub.
The global gene therapy market has been segmented based on type, route of administration, application, end use, and region:
By Type:
- Gene Silencing
- Cell Replacement
- Gene Augmentation
- Others
By Gene Type:
- Antigen
- Cytokine
- Tumor Suppressor
- Deficiency
- Growth Factors
- Receptors
- Others
By Application:
- Oncological Disorders
- Cardiological Diseases
- Infectious Diseases
- Rare Diseases
- Neurological Diseases
- Others
By End Use:
- Cancer Institutes
- Hospitals
- Research Centers
- Others
By Region:
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Asia Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Frequently Asked Questions!
- REGENXBIO, Inc.
- Oxford BioMedica plc
- Dimension Therapeutics, Inc.
- Bristol-Myers Squibb Company
- SANOFI
- Applied Genetic Technologies Corporation
- Hoffmann-La Roche Ltd
- Bluebird Bio, Inc.
- Novartis AG
- Taxus Cardium Pharmaceuticals Group, Inc.
- UniQure N.V.
- Shire Plc
- Cellectis S.A.
- Sangamo Therapeutics, Inc
- Orchard Therapeutics
- Gilead Lifesciences, Inc.
- BENITEC BIOPHARMA
- Sibiono GeneTech Co., Ltd
- Shanghai Sunway Biotech Co., Ltd.
- Gensight Biologics S.A.
- Transgene
- Calimmune, Inc.
- Epeius Biotechnologies Corp.
- Astellas Pharma Inc.
- American Gene Technologies
- BioMarin Pharmaceuticals, Inc.
To Learn More About This Report
Our Clients
